Claims for Patent: 9,707,269

Summary for Patent: 9,707,269

Title:	Sugar compositions for treating hemophilia A and/or von Willebrand disease
Abstract:	The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
Inventor(s):	Schulte; Stefan (Marburg, DE), Spirig; Rolf (Bern, CH), Zollner; Sabine (Muri, CH), Moses; Michael (Graevenwiesbach, DE), Wormsbaecher; Wilfried (Kirchhain, DE), Stoehr; Hans-Arnold (Wetter, DE)
Assignee:	CSL BEHRING GMBH (Marburg, DE)
Application Number:	14/399,326
Patent Claims:	1. A method of increasing the half-life of von Willebrand factor in the blood of a subject with hemophilia A and/or von Willebrand disease, comprising administering to the subject a composition comprising exogenous von Willebrand factor, and an isolated sugar that inhibits the interaction of von Willebrand factor with its clearance receptor, wherein the isolated sugar is an accessible sugar residue derived from ABO(H) blood group antigen, wherein the sugar is: a monosaccharide, which is one or more of unmodified galactose, fucose, and N-acetylgalactosamine. 2. The method of claim 1, wherein the in vivo clearance of von Willebrand factor is reduced. 3. The method of claim 2, wherein the reduction of in vivo clearance of von Willebrand factor leads to a concomitant increase in the area under the curve representing factor VIII concentration. 4. The method of claim 1, wherein the exogenous von Willebrand factor is plasma derived. 5. The method of claim 1, wherein the exogenous von Willebrand factor is recombinant. 6. The method of claim 1, wherein the composition is administered to the subject prior to administration of von Willebrand factor. 7. The method of claim 1, wherein the clearance receptor is a C-type lectin-like receptor. 8. The method of claim 7, wherein the C-type lectin-like receptor is selected from the subgroups asialoglycoprotein, DC receptors, and collectins. 9. The method of claim 7, wherein the C-type lectin-like receptor is selected from ASGPR, CLEC4M, CLEC10A, CLEC4F, and Collectin-12. 10. The method of claim 1, wherein the clearance receptor is a class A scavenger receptor comprising scavenger receptor A5 (SCARA5).

Details for Patent 9,707,269

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	December 08, 2015		2033-03-15